Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $471000.0.

  • TransMedics' Gains from Investment Securities fell 6806.78% to $471000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $80.5 million, marking a year-over-year increase of 16558.63%. This contributed to the annual value of $2.8 million for FY2024, which is 1567.31% down from last year.
  • TransMedics' Gains from Investment Securities amounted to $471000.0 in Q3 2025, which was down 6806.78% from $436485.0 recorded in Q1 2025.
  • TransMedics' 5-year Gains from Investment Securities high stood at $78.6 million for Q4 2024, and its period low was -$51000.0 during Q3 2023.
  • Moreover, its 5-year median value for Gains from Investment Securities was $1.5 million (2021), whereas its average is $8.5 million.
  • In the last 5 years, TransMedics' Gains from Investment Securities plummeted by 9393.64% in 2023 and then soared by 299215.69% in 2024.
  • TransMedics' Gains from Investment Securities (Quarter) stood at $2.8 million in 2021, then skyrocketed by 432.36% to $14.9 million in 2022, then soared by 93.57% to $28.8 million in 2023, then soared by 172.65% to $78.6 million in 2024, then crashed by 99.4% to $471000.0 in 2025.
  • Its last three reported values are $471000.0 in Q3 2025, $436485.0 for Q1 2025, and $78.6 million during Q4 2024.